Top Markets
Coin of the day
Cotinga Pharmaceuticals Inc. Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
Classifica tra le azioni #42319
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused... Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2026-07-02
Capitalizzazione di mercato
$2.20K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
CA
Scambia Cotinga Pharmaceuticals Inc. (COTQF)

Categoria

Rapporto P/B per Cotinga Pharmaceuticals Inc. (COTQF)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Cotinga Pharmaceuticals Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Cotinga Pharmaceuticals Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR